[
  {
    "sentence_num": 1,
    "sentence_id": "t041s001",
    "text": "Platelets play a pivotal role in primary hemostasis, thrombosis, inflammation, and vascular biology.",
    "tags": [
      "1c"
    ],
    "primary_tag": "1c",
    "move": "1"
  },
  {
    "sentence_num": 2,
    "sentence_id": "t041s002",
    "text": "These anuclear discoid cells circulate in the bloodstream to patrol the integrity of the vascular system[1].",
    "tags": [
      "1b"
    ],
    "primary_tag": "1b",
    "move": "1"
  },
  {
    "sentence_num": 3,
    "sentence_id": "t041s003",
    "text": "Upon injury, platelets quickly activate, change shape, release granule contents, and aggregate to form the hemostatic plug in the presence of fibrinogen.",
    "tags": [
      "1b"
    ],
    "primary_tag": "1b",
    "move": "1"
  },
  {
    "sentence_num": 4,
    "sentence_id": "t041s004",
    "text": "Platelet activation can be triggered by many physiological agonists, including thrombin, the most potent platelet agonist and a key protease in coagulation[2,3].",
    "tags": [
      "1b"
    ],
    "primary_tag": "1b",
    "move": "1"
  },
  {
    "sentence_num": 5,
    "sentence_id": "t041s005",
    "text": "Thrombin signals through two protease activated receptors (PARs), PAR1 and PAR4, on the surface of human platelets[4].",
    "tags": [
      "1c"
    ],
    "primary_tag": "1c",
    "move": "1"
  },
  {
    "sentence_num": 6,
    "sentence_id": "t041s006",
    "text": "PARs belong to the GPCR superfamily and have a unique activation mechanism whereby the N-terminus is enzymatically cleaved to unmask the tethered ligand[5].",
    "tags": [
      "1c"
    ],
    "primary_tag": "1c",
    "move": "1"
  },
  {
    "sentence_num": 7,
    "sentence_id": "t041s007",
    "text": "The new N-terminus interacts with the endogenous ligand binding site to induce a global structural rearrangement that activates downstream signaling[6,7].",
    "tags": [
      "1c"
    ],
    "primary_tag": "1c",
    "move": "1"
  },
  {
    "sentence_num": 8,
    "sentence_id": "t041s008",
    "text": "PAR1 and PAR4 both signal through Gαq and Gα12/13, however with different kinetics[8].",
    "tags": [
      "1c"
    ],
    "primary_tag": "1c",
    "move": "1"
  },
  {
    "sentence_num": 9,
    "sentence_id": "t041s009",
    "text": "PAR1 leads to rapid signaling that is quickly dissipated, whereas PAR4 leads to prolonged signaling[4,9,10].",
    "tags": [
      "1c"
    ],
    "primary_tag": "1c",
    "move": "1"
  },
  {
    "sentence_num": 10,
    "sentence_id": "t041s010",
    "text": "This sustained signaling associated with PAR4 activation is essential for thrombosis, highlighting PAR4 as a promising target for antiplatelet therapies[11–13].",
    "tags": [
      "1c"
    ],
    "primary_tag": "1c",
    "move": "1"
  },
  {
    "sentence_num": 11,
    "sentence_id": "t041s011",
    "text": "Over the past 10 years, platelet thrombin receptors have been appealing targets for antiplatelet therapies, which led to the first-in-class FDA approved PAR1 inhibitor, vorapaxar.",
    "tags": [
      "1c"
    ],
    "primary_tag": "1c",
    "move": "1"
  },
  {
    "sentence_num": 12,
    "sentence_id": "t041s012",
    "text": "However, targeting PAR1 comes with a significant risk of bleeding, which outweighs its clinical benefits in preventing cardiovascular events[14,15].",
    "tags": [
      "2c"
    ],
    "primary_tag": "2c",
    "move": "2"
  },
  {
    "sentence_num": 13,
    "sentence_id": "t041s013",
    "text": "In recent years, PAR4 has become a rising star as a safer antiplatelet and antithrombotic target for a number of reasons.",
    "tags": [
      "1c"
    ],
    "primary_tag": "1c",
    "move": "1"
  },
  {
    "sentence_num": 14,
    "sentence_id": "t041s014",
    "text": "First, targeting PAR4 signaling without inhibiting PAR1 allows platelets to continue to respond to low levels of thrombin and preserves normal hemostasis[12].",
    "tags": [
      "1c"
    ],
    "primary_tag": "1c",
    "move": "1"
  },
  {
    "sentence_num": 15,
    "sentence_id": "t041s015",
    "text": "Second, pharmacological inhibition of PAR4 prevents thrombin-mediated PAR4 activation at high concentrations that are associated with pathological thrombosis.",
    "tags": [
      "1c"
    ],
    "primary_tag": "1c",
    "move": "1"
  },
  {
    "sentence_num": 16,
    "sentence_id": "t041s016",
    "text": "Third, since the prolonged signaling mediated by PAR4 activation is associated with factor V release from α-granules and microparticle generation[16], selectively inhibiting PAR4 would not only prevent thrombus formation but also reduce platelet procoagulant activity[11].",
    "tags": [
      "1c"
    ],
    "primary_tag": "1c",
    "move": "1"
  },
  {
    "sentence_num": 17,
    "sentence_id": "t041s017",
    "text": "Collectively, this has culminated in the development of a number of PAR4 antagonists in the form of pepducins, small molecule compounds, and function-blocking antibodies[17].",
    "tags": [
      "1c"
    ],
    "primary_tag": "1c",
    "move": "1"
  },
  {
    "sentence_num": 18,
    "sentence_id": "t041s018",
    "text": "Two small molecule PAR4 inhibitors from Bristol Myers Squibb, BMS-986120 and BMS-986141, were the subject of clinical trials and proved to be efficient in preventing cardiovascular events with a good safety profile[12,13,18].",
    "tags": [
      "1c"
    ],
    "primary_tag": "1c",
    "move": "1"
  },
  {
    "sentence_num": 19,
    "sentence_id": "t041s019",
    "text": "PAR4’s unique properties have made it an attractive therapeutic target to prevent thrombosis without hindering normal hemostasis.",
    "tags": [
      "2d"
    ],
    "primary_tag": "2d",
    "move": "2"
  },
  {
    "sentence_num": 20,
    "sentence_id": "t041s020",
    "text": "Therefore, it is essential that we fully understand the mechanisms underlying PAR4 signaling.",
    "tags": [
      "3a"
    ],
    "primary_tag": "3a",
    "move": "3"
  },
  {
    "sentence_num": 21,
    "sentence_id": "t041s021",
    "text": "The tethered ligand mechanism was proposed in 1991 by Coughlin and colleagues, however the molecular mechanism of receptor activation is only recently understood.",
    "tags": [
      "1c"
    ],
    "primary_tag": "1c",
    "move": "1"
  },
  {
    "sentence_num": 22,
    "sentence_id": "t041s022",
    "text": "Recently, we used amide hydrogen/deuterium exchange (H/D exchange) mass spectrometry (MS) with purified full-length PAR4 to examine the conformational dynamics of the tethered ligand mechanism following activation by thrombin[19].",
    "tags": [
      "1c"
    ],
    "primary_tag": "1c",
    "move": "1"
  },
  {
    "sentence_num": 23,
    "sentence_id": "t041s023",
    "text": "This study revealed that PAR4 activation requires a coordinated rearrangement of extracellular loop 3 (ECL3) and threonine at position 153 in the ligand binding site formed by transmembrane domain 3 (TM3) and TM7.",
    "tags": [
      "3b"
    ],
    "primary_tag": "3b",
    "move": "3"
  },
  {
    "sentence_num": 24,
    "sentence_id": "t041s024",
    "text": "Within ECL3, there is a single nucleotide polymorphism (SNP) in which the proline at 310 is replaced with a leucine (PAR4-310P/L, rs2227376).",
    "tags": [
      "3b"
    ],
    "primary_tag": "3b",
    "move": "3"
  },
  {
    "sentence_num": 25,
    "sentence_id": "t041s025",
    "text": "This natural sequence variant of PAR4 had significantly lower receptor reactivity, as measured by calcium mobilization in HEK293 cells.",
    "tags": [
      "3b"
    ],
    "primary_tag": "3b",
    "move": "3"
  },
  {
    "sentence_num": 26,
    "sentence_id": "t041s026",
    "text": "Natural sequence variants of PAR4 (e.g. rs773902 (PAR4-120A/T), and rs2227346 (PAR4-296F/V)) affect the receptor reactivity and subsequent platelet function [20–23].",
    "tags": [
      "1c"
    ],
    "primary_tag": "1c",
    "move": "1"
  },
  {
    "sentence_num": 27,
    "sentence_id": "t041s027",
    "text": "Therefore, we hypothesize the hypo-reactive PAR4-P310L variant would reduce platelet responsiveness to thrombin stimulation",
    "tags": [
      "3b"
    ],
    "primary_tag": "3b",
    "move": "3"
  },
  {
    "sentence_num": 28,
    "sentence_id": "t041s028",
    "text": "To test the impact of the PAR4-310P/L polymorphism in vivo, we used CRISPR/Cas9 to introduce a point mutation into PAR4 to generate the mouse homolog of this variant, PAR4-P322L.",
    "tags": [
      "3b"
    ],
    "primary_tag": "3b",
    "move": "3"
  },
  {
    "sentence_num": 29,
    "sentence_id": "t041s029",
    "text": "PAR4-P322L significantly reduced platelet responsiveness to PAR4-activation peptide (AYPGKF) and thrombin, while ADP and GPVI signaling were not affected.",
    "tags": [
      "3c"
    ],
    "primary_tag": "3c",
    "move": "3"
  },
  {
    "sentence_num": 30,
    "sentence_id": "t041s030",
    "text": "Further, platelet aggregation was dramatically decreased in the platelets from mice that carried one (PAR4P/L, heterozygous) or two (PAR4L/L, homozygous) alleles of PAR4-P322L.",
    "tags": [
      "3c"
    ],
    "primary_tag": "3c",
    "move": "3"
  },
  {
    "sentence_num": 31,
    "sentence_id": "t041s031",
    "text": "Additionally, PAR4L/L mice displayed slightly extended tail bleeding compared to wild-types.",
    "tags": [
      "3c"
    ],
    "primary_tag": "3c",
    "move": "3"
  },
  {
    "sentence_num": 32,
    "sentence_id": "t041s032",
    "text": "PAR4-P322L also delayed arterial occlusion in the ferric chloride-induced carotid artery thrombosis model.",
    "tags": [
      "3c"
    ],
    "primary_tag": "3c",
    "move": "3"
  }
]